Free Trial

Mana Capital Acquisition (MAAQ) Competitors

$4.33 -0.43 (-9.03%)
As of 05/21/2025

MAAQ vs. GLSI, FTLF, LRMR, EDIT, EXOZ, ATOS, CGEN, NKTX, TARA, and ENTA

Should you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Greenwich LifeSciences (GLSI), FitLife Brands (FTLF), Larimar Therapeutics (LRMR), Editas Medicine (EDIT), Exozymes (EXOZ), Atossa Therapeutics (ATOS), Compugen (CGEN), Nkarta (NKTX), Protara Therapeutics (TARA), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry.

Mana Capital Acquisition vs.

Mana Capital Acquisition (NASDAQ:MAAQ) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.

Greenwich LifeSciences has a consensus price target of $39.00, indicating a potential upside of 297.96%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Mana Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Greenwich LifeSciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Greenwich LifeSciences received 8 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote.

CompanyUnderperformOutperform
Mana Capital AcquisitionOutperform Votes
1
100.00%
Underperform Votes
No Votes
Greenwich LifeSciencesOutperform Votes
9
47.37%
Underperform Votes
10
52.63%

Mana Capital Acquisition's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Mana Capital AcquisitionN/A N/A N/A
Greenwich LifeSciences N/A -185.12%-164.27%

In the previous week, Greenwich LifeSciences had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Greenwich LifeSciences and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat Greenwich LifeSciences' score of -3.00 indicating that Mana Capital Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
Mana Capital Acquisition Neutral
Greenwich LifeSciences Very Negative

68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mana Capital AcquisitionN/AN/AN/AN/AN/A
Greenwich LifeSciencesN/AN/A-$8.89M-$1.20-8.17

Summary

Greenwich LifeSciences beats Mana Capital Acquisition on 6 of the 11 factors compared between the two stocks.

Get Mana Capital Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MAAQ vs. The Competition

MetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$35.18M$35.18M$2.04B$8.39B
Dividend YieldN/AN/A2.64%4.11%
P/E RatioN/AN/A22.9219.71
Price / SalesN/AN/A60.71120.53
Price / CashN/AN/A51.7234.62
Price / BookN/AN/A2.064.50
Net IncomeN/AN/A-$292.00M$248.22M
7 Day Performance8.25%8.25%-0.39%-0.78%
1 Month Performance1,010.54%1,010.54%8.96%11.53%
1 Year Performance518.57%518.57%13.38%8.99%

Mana Capital Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MAAQ
Mana Capital Acquisition
N/A$4.33
-9.0%
N/A+518.6%$35.18MN/A0.001
GLSI
Greenwich LifeSciences
1.1735 of 5 stars
$9.74
+0.5%
$39.00
+300.4%
-27.4%$129.29MN/A-12.173Positive News
Earnings Report
FTLF
FitLife Brands
4.4196 of 5 stars
$13.64
-5.7%
$20.50
+50.3%
+0.0%$128.00M$64.47M16.1420Analyst Downgrade
Gap Up
LRMR
Larimar Therapeutics
2.0541 of 5 stars
$1.98
+5.9%
$19.63
+891.2%
-75.6%$126.78MN/A-1.7230Positive News
EDIT
Editas Medicine
4.2866 of 5 stars
$1.51
+8.2%
$5.36
+255.2%
-73.1%$126.40M$32.31M-0.59230
EXOZ
Exozymes
N/A$15.04
+10.9%
N/AN/A$125.86MN/A0.0029Gap Up
ATOS
Atossa Therapeutics
2.0187 of 5 stars
$0.97
-1.6%
$7.13
+634.5%
-43.1%$125.31MN/A-4.418
CGEN
Compugen
1.7576 of 5 stars
$1.39
+1.5%
$4.00
+187.8%
-37.2%$124.04M$27.86M69.5070News Coverage
Earnings Report
Analyst Revision
NKTX
Nkarta
1.9389 of 5 stars
$1.74
+1.2%
$14.67
+742.9%
-74.6%$123.47MN/A-0.93140
TARA
Protara Therapeutics
2.9167 of 5 stars
$3.19
+2.6%
$20.40
+539.5%
+6.0%$123.08MN/A-1.1330Positive News
Analyst Forecast
Gap Up
ENTA
Enanta Pharmaceuticals
3.8211 of 5 stars
$5.75
+7.1%
$17.25
+200.0%
-55.1%$122.67M$66.59M-1.16160Positive News

Related Companies and Tools


This page (NASDAQ:MAAQ) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners